louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04623645: Ultrasound Guided Superior Laryngeal Nerve Block Compared With Blind Block Technique
Official title: Ultrasound Guided Bilateral Superior Laryngeal Nerve Block Compared With Blind Block Technique For Awake Fibre-optic Intubation In Suspected Difficult Intubation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Airway Complication of Anesthesia
Keywords: Suspected Difficult Intubation
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2020-11-10
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve in surgical patient in comparison to blind anatomical technique.

Detailed description: Airway anesthesia is pivotal for successful awake intubation provided either topically or by nerves blocks. Airway blocks are technically harder to perform with more complications possibilities. However, in experienced hands, they can be useful as they provide better intubating conditions.

Eligibility criteria: Inclusion Criteria:

1. American Society of Anesthesiologists ( ASA ) physical status I and II.
2. Age between 40-60 years.
3. Modified Mallampati class III-IV .

Exclusion Criteria:

1. Local pathology of the neck.
2. Bleeding diathesis.
3. Allergy to local anesthetic agent.
4. Intellectual impairment.
5. Psychiatric disease.
6. Body mass index ≥30 kg/m2.

Primary outcomes:
measure: assessment the quality of airway anesthesia
timeFrame: Up to 2 years post baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alshaymaa Mortada Ali Eltohry
state: Please Select An Option
Study officials:
affiliation: Ain shams university, faculty of medicine
name: Azza Mohamed Shafik, professor
role: STUDY_CHAIR
affiliation: Ain shams university, faculty of medicine
name: Abeer Mohamed Abdel-Aziz, professor
role: STUDY_DIRECTOR
References:
citation: Manikandan S, Neema PK, Rathod RC. Ultrasound-guided bilateral superior laryngeal nerve block to aid awake endotracheal intubation in a patient with cervical spine disease for emergency surgery. Anaesth Intensive Care. 2010 Sep;38(5):946-8. doi: 10.1177/0310057X1003800523.
citation: Ramkumar V. Preparation of the patient and the airway for awake intubation. Indian J Anaesth. 2011 Sep;55(5):442-7. doi: 10.4103/0019-5049.89863.
Clinical trial NCT05258045: Validity of Mediastinal Blood Pool SUV Ratio
Official title: Is Mediastinal Blood Pool SUV Ratio Valid in Identification of Malignancy in Comparison to Liver SUV Ratio?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Validity of Blood Pool SUV Ratio in Identification of Malignancy in Case of Diseased Liver
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2022-02-28
Enrollment: 55
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Cross sectional study prospective and retrospective

Brief summary: -Validity of blood pool SUV ratio in identification of malignancy in case of diseased liver.

Detailed description: PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer tissues by using flourine 18 FDG which is FDA approved and used routinely in identification of malignant lesions , staging and restaging of many malignancy like lymphoma, breast cancer, lung cancer and cancer colon.

In clinical routine, SUV is often used to determine the glucose metabolism in tumours by 18F-FDG PET/CT. And can be further normalised to SUVs in reference regions resulting in a SUV ratio (SUV ratio).in routine work SUV of the lesion is normalised to SUV of the liver , but this not used if the liver is diseased like as liver cirrhosis or liver metastases , so SUV ratio of lesion to mediastinal blood pool and SUV ratio of the lesion to liver will be measured in correlation to pathology to assess validity of SUV of mediastinal blood pool.

Eligibility criteria: Inclusion Criteria:

* This study will include cancer pt who did PET/CT scan who presented to nuclear medicine unit during the period from 2021 until the end of the study.

Exclusion Criteria:

* Severely ill patient
* Pt with glucose level above 200

Primary outcomes:
measure: -Validity of blood pool suv ratio in identification of malignancy in case of diseased liver.
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06763445: Exploring the Relationship Between Caring Experience, Perceived Behavioral Control, and Caring Intention Among Students
Official title: Exploring the Relationship Between Caring Experience, Perceived Behavioral Control, and Caring Intention Among University Students
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Caring
Lead sponsor: Central Taiwan University of Science and Technology
Sponsor class: OTHER
First posted: 2025-01-08
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: students

Brief summary: This research project conducts a relevant investigation into the past background and learning experiences of university students during the process of caring. Additionally, it aims to understand the correlations between different scales.


Eligibility criteria: Inclusion Criteria:

* University students aged 18 and above.

Exclusion Criteria:

* University students who refuse or are unwilling to participate.

Primary outcomes:
measure: Caring Intention
timeFrame: Baseline. Will be collected only once.
Secondary outcomes:
measure: caring assessment scale
timeFrame: Baseline. Will be collected only once
measure: Perceived Behavioral Control for caring
timeFrame: Baseline. Will be collected only once.
measure: Caring Experience
timeFrame: Baseline. Will be collected only once.
measure: caring ability inventory
timeFrame: Baseline. Will be collected only once.
measure: Selfishness questionnaire
timeFrame: Baseline. Will be collected only once.
measure: Scale for Measuring Changes in Ideas About Caring
timeFrame: Baseline. Will be collected only once.
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Central Taiwan University of Science and Technology
Study officials:
References:
Clinical trial NCT01066845: Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
Official title: Safety and Effectiveness of Adcirca (Tadalafil) in Japanese Patients With Pulmonary Arterial Hypertension: Open-label, Non-interventional Observational Study in Japan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Arterial Hypertension
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2010-02-10
Enrollment: 1809
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Japanese patients prescribed Adcirca from clinical practices

Brief summary: To investigate the long-term safety and effectiveness of Adcirca (tadalafil) in Pulmonary Arterial Hypertension (PAH) patients in the clinical practice -focused topics-

1. To evaluate the incidence of adverse events for the patients with long-term use
2. To evaluate the incidence of adverse events of decreased blood pressure, bleeding (including uterine hemorrhage), visual disturbance and sudden hearing loss.


Eligibility criteria: Inclusion Criteria:

* Patients with PAH receiving Adcirca

Exclusion Criteria:Patients who meet the criteria of contraindication

* patients with hypersensitivity to tadalafil
* patients who are using any form of organic nitrate
* patients with severe renal impairment
* patients with severe hepatic impairment
* patients taking strong inhibitors of CYP3A4
* patients taking strong inducers of CYP3A4

Primary outcomes:
measure: The incidence of adverse events related to decreased blood pressure, bleeding, visual disturbance and sudden hearing loss.
timeFrame: 2 years
Secondary outcomes:
measure: 6 minute walk distance change from baseline
timeFrame: 2 years
measure: World Health Organization (WHO) functional class change from baseline
timeFrame: 2 years
measure: Survival time
timeFrame: 2 years
measure: Pulmonary arterial pressure change from baseline
timeFrame: 2 years
measure: Score change of Euro Quality of Life (EQ-5D) from baseline
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT04483245: Platelet Activation by a Collagen Analogue in Hemorrhagic Situations
Official title: Platelet Activation by a Collagen Analogue in Hemorrhagic Situations
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Collagen Analog
Platelet Activation
Hemorrhage
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2020-07-23
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients coming for a consultation at the Resouce Centre for Haemorrhagic Diseases and Coagulopathies in the Internal Medicine and Haematology Department. Patients admitted to the Emergency Department, and patients admitted to the operating theatre by the Surgical Intensive Care Unit, the Neurovascular Emergency Department, or the Neurosurgery Department.

Brief summary: Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular, non-fibrillar presentation make it suitable for use as an injectable hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.


Eligibility criteria: Inclusion Criteria:

* - person who has given their non-opposition to inclusion
* adult
* Healthy volunteers or controls (patients seen in consultation, without history of hemmorhage, etc.).

or

* patients with acute bleeding: polytraumatized, or hemorrhage or intracerebral haemorrhage, or bleeding complications at the end surgery (in particular cardiac surgery with ECMO) or
* patients with antiplatelet therapy or
* patients with thrombocytopenia/thrombopathy

Exclusion Criteria:

* protected adults (curatorship, guardianship)
* person deprived of their liberty by judicial or administrative decision
* pregnant, parturient or breastfeeding woman
* person unable to express their non-opposition
* platelet transfusion on initial management

Primary outcomes:
measure: The expression of P-selectin and activated GPIIb/IIIa (PAC1) at the surface of platelets in flow cytometry in response to NVH020B.
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Platelet aggregation rate in response to NVH020B
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
city: Dijon
country: France
facility: Chu Dijon Bourgogne
Study officials:
References:
Clinical trial NCT06498245: Early Abdominal Wall Prosthesis Infections: Epidemiology, Risk Factors and Factors Linked to Recovery
Official title: Early Abdominal Wall Prosthesis Infections: Epidemiology, Risk Factors and Factors Linked to Recovery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Abdominal Wall Prosthesis Infections
Keywords: Abdominal wall prosthesis
Antibiotic therapy
Surgical revision
Abdominal wall
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2024-07-12
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major subject (≥18 years old) operated on at the HUS in the department of Pr. Rohr between January 1, 2017 and July 26, 2023

Brief summary: Abdominal wall prosthesis infections are among the complications most feared by digestive surgeons. Indeed, this complication is associated with high morbidity and is difficult to manage (antibiotic therapy? surgical revision?). Much data is missing in the literature because there are many types of prosthesis, implemented in patients with very varied conditions and the treatment is not strictly speaking codified.

The investigators wish to carry out a retrospective study on approximately 500 patients and research the main characteristics of the different infections (which microorganism? which site? what time of appearance), the factors linked to the appearance of these infections and above all how to optimize their management. charge.


Eligibility criteria: Inclusion Criteria:

* Major subject (≥18 years old)
* Subject operated on at the HUS in the department of Pr. Rohr between January 1, 2017 and July 26, 2023
* Operation of an incisional hernia cure with installation of an abdominal wall prosthesis
* Absence of written opposition in the subject's medical file to the reuse of their data for scientific research purposes.

Exclusion Criteria:

* Subject having expressed his opposition to the reuse of his data for scientific research purposes.

Primary outcomes:
measure: Recovery of wall prosthesis infection after 3 months from the start of the infection
timeFrame: 3 months from the start of the infection of the prothesis
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT05137405: THE IMPACT OF COVID-19 AMONG OBESE PATIENTS
Official title: HOW THE IMPACT OF COVID-19 HOME STAY ORDERS IS AFFECTING THE PHYSICAL, MENTAL AND FINANCIAL HEALTH AMONG OBESE PATIENTS?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obesity, Morbid
Lead sponsor: University of Foggia
Sponsor class: OTHER
First posted: 2021-11-30
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.

Brief summary: BACKGROUND: Stay-at-home orders in response to the Coronavirus 2 (SARSCoV-2) have forced abrupt changes to daily routines.

The aim of our study is to evaluate the impact of the Stay-at-home orders on the waiting list for bariatric surgery in our Department of Medical and Surgical during covid-19 pandemic.

MATERIALS AND METHODS: In this observational retrospective study, from the 9th of March to 18th May 2020, the patients of our Department were invited to answer to a 14-questions multiple-choice questionnaire relative to weight changes, working activity, daily exercise, dietary behaviors, and conditions potentially impacting the nutritional choices


Eligibility criteria: Inclusion Criteria:

- Alle obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical during covid-19 pandemic from March to May 2020

Exclusion Criteria:

- Patients underwent bariatric surgery

Primary outcomes:
measure: evaluate the impact of the Lock-down period on the mental and physical health of obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences during covid-19 pandemic.
timeFrame: March - May 2020
Secondary outcomes:
Other outcomes:
Locations:
city: Foggia
country: Italy
facility: Nicola Tartaglia
Study officials:
References:
Clinical trial NCT01390805: Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
Official title: Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Genital Herpes
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2011-07-11
Enrollment: 462
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Japanese subjects with recurrent genital herpes

Brief summary: The purpose of this study is to collect and assess information on proper use of valaciclovir regarding safety and efficacy of long-term use in suppressive therapy for subjects with recurrent genital herpes.


Eligibility criteria: Inclusion Criteria:

* Subjects who started suppressive therapy for recurrent genital herpes for the first time

Exclusion Criteria:

* Subjects with a history of hypersensitivity to the ingredients of VALTREX or aciclovir

Primary outcomes:
measure: The number of adverse events in Japanese subjects with recurrent genital herpes treated with valaciclovir
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT02619305: Social Network Outcomes of a Livelihood Intervention for Impoverished Women in Rural Uganda
Official title: Social Network Outcomes of a Livelihood Intervention for Impoverished Women in Rural Uganda: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Indigency
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Mbarara University of Science and Technology
First posted: 2015-12-02
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The objective of our study is to determine whether a livelihood intervention can change economic and psychosocial outcomes of social network ties and geographically proximate neighbors of impoverished women in rural Uganda.


Eligibility criteria: Inclusion Criteria:

* Eligibility will be limited to all adults living in Nyakabare Parish (i.e., aged 18 years and older), including emancipated minors. Emancipated minors will be defined as persons living below 18 years of age who are married, are pregnant, live with a biological child in the household, or are responsible for their own livelihood.

Exclusion Criteria:

* Persons under the age of 18 (other than emancipated minors as described above) and persons who do not live within Nyakabare Parish will not be permitted to participate.

Primary outcomes:
measure: Household Food Insecurity Access Scale
timeFrame: 12 months
measure: Hopkins Symptom Checklist Scale
timeFrame: 12 months
Secondary outcomes:
measure: HIV Stigma Scale
timeFrame: 12 months
measure: Norms about Intimate Partner Violence Scale
timeFrame: 12 months
measure: Social Integration Scale
timeFrame: 12 months
measure: Social Capital Scale
timeFrame: 12 months
Other outcomes:
Locations:
city: Mbarara
country: Uganda
facility: Mbarara University of Science and Technology
Study officials:
affiliation: Massachusetts General Hospital
name: Alexander C Tsai, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mbarara University of Science and Technology
name: Bernard Kakuhikire, MBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05090605: The Role of Genetic Factors in the Development of Breast Cancer in the Kazakh Population
Official title: Preventive and Personalized Medicine (2021-2023)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: GWAS
Lead sponsor: Asfendiyarov Kazakh National Medical University
Sponsor class: OTHER
First posted: 2021-10-25
Enrollment: 700
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: in a group of breast cancer, in the Kazakh population

Brief summary: This is a GWAS study that aims to identify possible candidate genes associate to breast cancer by exploring single nucleotide polymorphism (SNP) in a group of breast cancer, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with breast cancer

Detailed description: A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Eligibility criteria: Inclusion Criteria:

* Persons with a histologically confirmed diagnosis of breast cancer.
* The age of patients is from 18 to 60 years;
* Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs.
* Persons who are able and willing to provide written informed consent;
* Persons capable and willing to comply with the research protocol;

Exclusion Criteria:

* Persons under 18 and over 60 years old;
* Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
* Pregnant or lactating women;
* Tuberculosis of any localization in the active phase and in history;
* Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
* Severe and decompensated course of endocrine diseases;
* Lack of histological verification of breast tumor

Primary outcomes:
measure: number of SNPs associated with breast cancer
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Almaty
country: Kazakhstan
facility: JSC "Kazakh Institute of Oncology and Radiology"
city: Almaty
country: Kazakhstan
facility: JSC "Kazakh Institute of Oncology and Radiology", Almaty, Kazakhstan
Study officials:
affiliation: JSC "Kazakh Institute of Oncology and Radiology", Almaty, Kazakhstan
name: Dilyara Radikovna Kaidarova, M.D, Prof., Academician of the
role: STUDY_DIRECTOR
affiliation: JSC "Kazakh Institute of Oncology and Radiology", Almaty, Kazakhstan
name: Nazgul Omarbayeva, M.D / PhD
role: PRINCIPAL_INVESTIGATOR
References: